Xiao-Jian Wang1, Jia-Zhou Lin2, Shu-Han Yu3, Sheng-Xi Wu4, He-San Luo4, Ze-Sen Du5, Xu-Yuan Li3. 1. Department of Pharmacy, Shantou Central Hospital, Shantou, China. 2. Department of Clinical Laboratory Medicine, Cancer Hospital of Shantou University Medical College, Shantou, China. 3. Department of Medical Oncology, Shantou Central Hospital, Shantou, China. 4. Department of Radiation Oncology, Shantou Central Hospital, Shantou, China. 5. Department of Surgical Oncology, Shantou Central Hospital, Shantou, China.
Abstract
AIM: To estimate efficacy of checkpoint inhibitors and rank treatment effects in non-small-cell lung cancer. MATERIALS & METHODS: Prospective randomized trials were included. p-score was used to rank treatment effects. RESULTS: A total of nine trials were identified, involving 5504 patients and three checkpoint inhibitors. Pembrolizumab plus chemotherapy had the highest p-score of 0.95 among all the treatments, and was superior to pembrolizumab alone (hazard ratio: 0.87; 95% CI: 0.79-0.95). Combination therapy had more grade 3-5 adverse events; but toxicity-related discontinuation and treatment-related death did not increase. CONCLUSION: Pembrolizumab plus chemotherapy was likely to be the most effective treatment for patients with wild-type advanced NSCLC.
AIM: To estimate efficacy of checkpoint inhibitors and rank treatment effects in non-small-cell lung cancer. MATERIALS & METHODS: Prospective randomized trials were included. p-score was used to rank treatment effects. RESULTS: A total of nine trials were identified, involving 5504 patients and three checkpoint inhibitors. Pembrolizumab plus chemotherapy had the highest p-score of 0.95 among all the treatments, and was superior to pembrolizumab alone (hazard ratio: 0.87; 95% CI: 0.79-0.95). Combination therapy had more grade 3-5 adverse events; but toxicity-related discontinuation and treatment-related death did not increase. CONCLUSION:Pembrolizumab plus chemotherapy was likely to be the most effective treatment for patients with wild-type advanced NSCLC.